Gamida Cell
Gamida Cell Q1 FY24: revenue $890K; diluted EPS $0.13
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001213900-24-046302
- Document
- 10-Q
Key figures from this report
These are the numbers Gamida Cell reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$890KNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$19.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS$0.13No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$24.8MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
- Cash from operations−$23.0MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR
Similar companies
Same SIC code (2836) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX
